ClinicalTrials.gg
RecruitingNCT07423117Updated Nov 10, 2026

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

A Phase 1 interventional study of ITC-6146RO in Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer and Triple Negative Breast Cancer, sponsored by IntoCell, Inc. Recruiting at 3 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by IntoCell, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 10, 2026Now RecruitingNow Enrolling by invitation+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of — 124 open to participants now, 264 under way, 101 of them phase 3. Carcinoma, Non-Small-Cell Lung · Korea, Republic of.

Planned enrollment
461st of 659
102 · median 200
Started
2026
with 23 others
Phase 1
109 of 702
20 open now
Primary completion
2027-06
later than 131 of 263 live
Registered
686th of 702
by date

Among the 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, this one is the 461st largest by planned enrollment of the 659 interventional ones that give a count, is one of 24 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 131 of the 263 other live ones, and was the 686th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

124 of the 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of are open now. Recruiting first, the newest first:

118 more — sign in →

All 124 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal biological dose (OBD).

In Phase 1b, the recommended phase 2 dose (RP2D) chosen from Phase 1a will be evaluated to further investigate safety, tolerability, pharmacokinetic (PK) and anti-tumor efficacy of ITC-6146RO.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer
  • Non-small Cell Lung Cancer
  • Triple Negative Breast Cancer
  • Metastatic Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males and females aged ≥ 19 years (Korea) or ≥ 18 years (United States)
  2. Patients must be individuals who have voluntarily agreed to participate in the study after receiving a detailed explanation and fully understanding the nature of the clinical trial, and who have provided written .
  3. Pathological confirmation of and evidence of or surgically unresectable disease
  4. Patients must have at least one evaluable or based on Version 1.1 (RECIST version 1.1). However, for patients with prostate cancer, eligibility will be determined based on Prostate Cancer Working Group 3 (PCWG3)
  5. Patients who have received standard therapies and have no remaining clinically available approved treatment options.
  6. (ECOG) performance status 0 or 1
  7. Estimated of ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  1. Inability to comply with study and follow-up procedures
  2. Patients with a prior history of anticancer therapy before the first dose
  3. History of another active within the past 3 years
  4. Patients with central nervous system , , or spinal cord compression.
  5. Patients who are currently participating in a clinical trial or have participated in a clinical trial involving a medical device or product within 28 days prior to the first administration of ITC-6146RO
  6. Has prior treatment with duocarmycin-containing agents
  7. Pregnancy, lactation, or breastfeeding
  8. Known (HIV), virus (HCV) and virus (HBV) infection with active disease exception of the following conditions.
  9. Tuberculosis with active disease
  10. Active infection necessitating systemic therapy
  11. Prior allogenic bone marrow transplantation or solid organ transplantation
  12. History of disease, treatment with systemic medications
  13. Patients with pulmonary disease
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Phase 1a/b

    The study consists of a Phase 1a dose-escalation part and a Phase 1b dose-expansion part.

    Drug: ITC-6146RO

Interventions

  • DrugITC-6146RO

    ITC-6146RO will be administered as an intravenous (IV) infusion at protocol-specified dose levels and schedules in Phase 1a (dose escalation) and Phase 1b (dose expansion).

06

What researchers measure

Primary outcomes

  1. Phase 1a (Dose Escalation) Incidence of Adverse Events (AEs)

    Grade 3 and 4 AEs, Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Dose-limiting toxicities (DLTs) and AEs leading to discontinuation of study treatment, Evaluation of all-grade cardiac, renal, and pulmonary AEs , n, (%)

    Time frame: Through study completion (Up to 2 years)

  2. Phase 1b (Dose Expansion) Incidence of AEs

    Grade 3 and 4 AEs, TEAEs, SAEs and AEs leading to discontinuation of study treatment, Evaluation of all-grade cardiac, renal, and pulmonary AEs, n, %

    Time frame: Through study completion (Up to 2 years)

Secondary outcomes

  1. Phase 1a (Dose Escalation) Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of ITC-6146RO

    MTD/OBD will be reported as the final selected dose level for further investigation from Phase 1a dose escalation. MTD is determined by DLTs observed during the prespecified DLT observation period, and OBD is determined by meeting prespecified biological activity criteria (as defined in the protocol).

    Time frame: Through study completion (Up to 2 years)

  2. Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) After Single-Dose Administration of ITC-6146RO

    Plasma AUClast following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  3. Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) After Single-Dose Administration of ITC-6146RO

    Plasma AUCinf following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  4. Phase 1a (Dose Escalation) Maximum Observed Plasma Concentration (Cmax) After Single-Dose Administration of ITC-6146RO

    Plasma Cmax following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  5. Phase 1a (Dose Escalation) Terminal Elimination Half-life (t1/2) After Single-Dose Administration of ITC-6146RO

    Plasma terminal elimination half-life (t1/2) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  6. Phase 1a (Dose Escalation) Time to Maximum Observed Plasma Concentration (Tmax) After Single-Dose Administration of ITC-6146RO

    Plasma Tmax following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  7. Phase 1a (Dose Escalation) Apparent Clearance (CL) After Single-Dose Administration of ITC-6146RO

    Plasma apparent clearance (CL) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  8. Phase 1a (Dose Escalation) Apparent Volume of Distribution (Vz) After Single-Dose Administration of ITC-6146RO

    Plasma apparent volume of distribution (Vz) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  9. Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) After Multiple-Dose Administration of ITC-6146RO

    Plasma AUClast following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  10. Phase 1a (Dose Escalation) Maximum Observed Plasma Concentration at Steady State (Cmax,ss) After Multiple-Dose Administration of ITC-6146RO

    Plasma Cmax,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  11. Phase 1a (Dose Escalation) Trough Plasma Concentration at Steady State (Ctrough,ss) After Multiple-Dose Administration of ITC-6146RO

    Plasma Ctrough,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  12. Phase 1a (Dose Escalation) Average Plasma Concentration Over the Dosing Interval at Steady State (Cav,τ) After Multiple-Dose Administration of ITC-6146RO

    Plasma Cav,τ (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  13. Phase 1a (Dose Escalation) Terminal Elimination Half-life at Steady State (t1/2,ss) After Multiple-Dose Administration of ITC-6146RO

    Plasma terminal elimination half-life at steady state (t1/2,ss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  14. Phase 1a (Dose Escalation) Time to Maximum Observed Plasma Concentration at Steady State (Tmax,ss) After Multiple-Dose Administration of ITC-6146RO

    Plasma Tmax,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  15. Phase 1a (Dose Escalation) Apparent Clearance at Steady State (CLss) After Multiple-Dose Administration of ITC-6146RO

    Plasma apparent clearance at steady state (CLss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  16. Phase 1a (Dose Escalation) Apparent Volume of Distribution at Steady State (Vss) After Multiple-Dose Administration of ITC-6146RO

    Plasma apparent volume of distribution at steady state (Vss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  17. Phase 1a (Dose Escalation) Accumulation Ratio After Multiple-Dose Administration of ITC-6146RO

    Accumulation ratio (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  18. Phase 1a (Dose Escalation) Peak-to-Trough Fluctuation (PTF) After Multiple-Dose Administration of ITC-6146RO

    Peak-to-trough fluctuation (PTF) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively.

    Time frame: Through study completion (Up to 2 years)

  19. Phase 1a (Dose Escalation) Incidence of Anti-Drug Antibodies (ADAs) to ITC-6146RO

    Percentage of participants with detectable ADAs to ITC-6146RO (ADA-positive) based on a validated immunoassay.

    Time frame: Through study completion (Up to 2 years)

  20. Phase 1b (Dose Expansion) Population Pharmacokinetic (PopPK) Parameters of ITC-6146RO

    PopPK parameters (e.g.,clearance and volume of distribution) will be estimated using PopPK modeling based on measured ITC-6146RO concentrations.

    Time frame: Through study completion (Up to 2 years)

  21. Phase 1b (Dose Expansion) Incidence of Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to ITC-6146RO

    Percentage of participants with detectable ADAs, including NAbs, to ITC-6146RO, as determined by validated immunoassay and neutralization assays (as applicable).

    Time frame: Through study completion (Up to 2 years)

  22. Phase 1a/b (Dose Escalation, Dose Expansion) Objective Response Rate (ORR) by Investigator per RECIST v1.1

    ORR will be assessed by the investigator per RECIST v1.1

    Time frame: Through study completion (Up to 2 years)

  23. Phase 1a/b (Dose Escalation, Dose Expansion) Duration of Response (DoR) by Investigator per RECIST v1.1

    DoR will be assessed by the investigator per RECIST v1.1

    Time frame: Through study completion (Up to 2 years)

  24. Phase 1a/b (Dose Escalation, Dose Expansion) Time to Response (TTR) by Investigator per RECIST v1.1

    TTR will be assessed by the investigator per RECIST v1.1

    Time frame: Through study completion (Up to 2 years)

  25. Phase 1a/b (Dose Escalation, Dose Expansion) Progression-Free Survival (PFS) by Investigator per RECIST v1.1

    PFS will be assessed by the investigator per RECIST v1.1

    Time frame: Through study completion (Up to 2 years)

Other outcomes

  1. Phase 1b (Dose Expansion) Association Between ITC-6146RO Pharmacokinetic Parameters and Efficacy and Safety Endpoints

    Correlation between ITC-6146RO pharmacokinetic (PK) parameters and selected efficacy, safety, and exploratory endpoints. Efficacy endpoints may include objective response rate (ORR) and progression-free survival (PFS). Associations will be evaluated using appropriate exposure-response analyses.

    Time frame: Through study completion (Up to 2 years)

  2. Phase 1a/b (Dose Escalation, Dose Expansion) Overall Survival (OS)

    OS is defined as the time from randomization until death from any cause.

    Time frame: Through study completion (Up to 2 years)

  3. Phase 1a/b (Dose Escalation, Dose Expansion) Association Between B7-H3 Expression in Tumor Tissue and Anti-Tumor Efficacy

    Correlation between B7-H3 expression in tumor tissue assessed by immunohistochemistry (IHC) and anti-tumor efficacy endpoints, including objective response rate (ORR) and progression-free survival (PFS). ORR is defined as the proportion of participants with confirmed complete or partial response, and PFS as time to disease progression or death per protocol-defined criteria. Associations will be evaluated using appropriate statistical methods. In participants with metastatic castration-resistant prostate cancer (mCRPC), PSA response rate (≥50% decline from baseline) and time to PSA progression will also be assessed.

    Time frame: Through study completion (Up to 2 years)

07

Study locations

3 of 3 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 15 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 20, 2026
StartActual
Mar 24, 2026was Feb 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation→Recruiting
changed Nov 4, 2026 · changed Nov 10, 2026
Sites
3 sites added — first site in South Korea. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Severance Hospital · Seoul, South Koreano status→Recruiting
  • Asan Medical Center · Seoul, South Koreano status→Recruiting
  • Samsung Medical Center · Seoul, South Koreano status→Recruiting
Show 3 added (3 South Korea)
  • Severance Hospital · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Samsung Medical Center · Seoul, South Korea
across 2 updates, Nov 4, 2026 – Nov 10, 2026
Start date
Feb 6, 2026→Mar 24, 2026 (actual)
Nov 4, 2026
Contact
Study contact now listed: added e•••@intocell.com · •••3589; added s•••@intocell.com · •••7484. See the current contact
Nov 10, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Severance Hospital · Seoul, South KoreaContact added O•••@yuhs.ac · •••6064
  • Asan Medical Center · Seoul, South KoreaContact added l•••@amc.seoul.kr · •••7384
  • Samsung Medical Center · Seoul, South KoreaContact added s•••@gmail.com · •••2977
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Enrolling by invitation→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Severance Hospital · Seoul, South Koreano status→Recruiting
    • Asan Medical Center · Seoul, South Koreano status→Recruiting
    • Samsung Medical Center · Seoul, South Koreano status→Recruiting
    Contact Study contact now listed: added e•••@intocell.com · •••3589; added s•••@intocell.com · •••7484. See the current contact
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Severance Hospital · Seoul, South KoreaContact added O•••@yuhs.ac · •••6064
    • Asan Medical Center · Seoul, South KoreaContact added l•••@amc.seoul.kr · •••7384
    • Samsung Medical Center · Seoul, South KoreaContact added s•••@gmail.com · •••2977
  2. Nov 4, 2026
    Not yet recruiting→Enrolling by invitation
    3 sites added — first site in South Korea
    Show 3 added (3 South Korea)
    • Severance Hospital · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Samsung Medical Center · Seoul, South Korea
    Start date Feb 6, 2026→Mar 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07423117
Lead sponsor
IntoCell, Inc
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Mar 24, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

EUNJU JEON, PhD
Contact
ejjeon@intocell.com
010-7557-3589 ext. 042-716-0151
SOOJIN OH, MS
Contact
sjoh@intocell.com
010-7664-7484 ext. 042-716-0339

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion